Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-02-18
1997-04-29
Carr, Deborah D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 855, 424 851, 424 852, 424 854, 424 856, 424 857, 514866, A61K 3810, A61K 3819, A61K 3820, A61K 3821
Patent
active
056248954
ABSTRACT:
A method for treating and/or preventing Type I diabetes mellitus in mammals and humans by administration of at least one of the following: (i) gamma interferon, (ii) an analog of gamma interferon or (iii) an inducer of gamma interferon thereof is taught. The use of gamma interferon, analogs thereof, or gamma interferon inducers to prevent recurrent Type I diabetes mellitus in transplant subjects is also provided.
REFERENCES:
"Defective HLA Class II Expression in Monocytes of Type I Diabetic Patients", APMIS vol. 101, pp. 395-402, May 1993.
"Evidence of Circulating Interferon-.gamma. in Newly Diagnosed Diabetic Children", Acta Paediatr. Scand., vol. 73, No. 6, pp. 785-788, Nov. 1984.
"Interferon-.gamma. Increases Susceptibility of Murine Pancreatic Beta Cells to Lysis by Allogeneic Cytotoxic T Lymphocytes", Autoimmunity, vol. 8, No. 2, pp. 135-141, Jun. 1990.
"Insulin-Dependent Diabetes Mellitus Induced in Transgenic Mice by Ectopic Expression of Class II MHC and Interferon-Gamma", Cell, vol. 52, No. 5, pp. 773-782, Mar. 11, 1988.
"Cytokines and the Pathogenesis of Insulin-Dependent Diabetes Mellitus", Cleveland Clinic Journal of Medicine, vol. 59, No. 6, pp. 629-632, Nov.-Dec. 1992.
"Transgenic Models of Diabetes", Current Opinion in Immunology, vol. 2, No. 4, pp. 604-606, 1990.
"Prevention of Autoimmune Diabetes With Nonactivating Anti-CD3 Monoclonal Antibody", Diabetes, vol. 41, No. 3, pp. 385-391, Mar. 1992.
"Interferon May Offer First Drug Therapy for Diabetic Retinopathy", Diabetes Care, vol. 15, No. 2, pp. 300-301, Feb. 1992.
"Remission in Newly Diagnosed Type II (Insulin-Dependent) Diabetes: Influence of Interferon as an Adjunct to Insulin Therapy", Diabetologia, vol. 27, No. 2, pp. 193-197, Aug. 1984.
"Overexpression of Class I Major Histocompatibility Complex Accompanies Insulitis in the Non-Obese Diabetic Mouse and is Prevented by Anti-Interferon-.gamma. Antibody", Diabetologia, vol. 34, pp. 779-785, 1991.
"Prevention of Diabetes in NOD Mice Treated with Antibody to Murine IFN.gamma.", Journal of Autoimmunity, vol. 4, No. 2, pp. 237-248, 1991.
"Reduction in Insulitis Following Administration of IFN-.gamma. and TNF-.alpha. in the MOD Mouse", Journal of Autoimmunity, vol. 4, No. 2, pp. 249-262, Apr. 1991.
"Immunostimulation Circumvents Diabetes in NOD/Lt Mice", Journal of Autoimmunity, vol. 2, pp. 759-776, 1989.
"Role of Tumor Necrosis Factor-.alpha. and Interferon-.gamma. as Growth Factors to the Human Fetal .beta.-Cell", Clinical Endocrinology & Metabolism, vol. 73, No. 5, pp. 1044-1050, 1991.
"Essential Role for Interferon-.gamma. and Interleukin-6 in Autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice", The Journal of Clinical Investigation, vol. 87, pp. 739-742, Feb. 1991.
"The Role of Interferon in Virus-Induced Diabetes", The Journal of Infectious Diseases, vol. 147, No. 1, pp. 155-159, Jan. 1983.
"The Role of Interferon in the Protection of ICR Swiss Male Mice by the Nondiabetogenic Variant of Encephalomyocarditis Virus Against Virus-Induced Diabetes Mellitus", Journal of Interferon Research, vol. 9, No. 6, Dec. 1989.
"FN-.gamma. Receptor-Ig Fusion Proteins Hal-Life, Immunogenicity, and in Vivo Activity", The Journal of Immunology, vol. 149, No. 12, pp. 4096-4100, Dec. 1992.
"Insulitis in Type I (Insulin-Dependent) Diabetes Mellitus in Man-Macrophages, Lymphocytes, and Interferon-.gamma. Containing Cells", Journal of Pathology, vol. 165, No. 2, pp. 97-103, 1991.
"Development of Type 1 Diabetes Mellitus During Interferon Alfa Therapy for Chronic HCV Hapatitis", The Lancet, vol 340, p. 548, Aug. 29, 1992.
"Loss of Pancreatic Islet Tolerance Induced by .beta.-Cell Expression of Interferon-.gamma.", Nature, vol. 346, No. 6287, pp. 844-847, Aug. 30, 1990.
"Nitric Oxide Mediates Cytokine-Induced Inhibition of Insulin Secretion by Human Islets of Langerhans", Proceedings of the National Academy of Sciences, vol. 90, No. 5, pp. 1731-1735, Mar. 1993.
"Induction of Type I Diabetes by Interferon-.alpha. In Transgenic Mice", Science, vol. 260, pp. 1942-1946, Jun. 25, 1993.
"Tumor Necrosis Factor and Interferon Gamma: Relevance for Immunoregulation and Genetic Predisposition to Autoimmune Disease", Seminars in Immunology, vol. 4, No. 3, 1992.
Oya et al, "Restoration of Immune-Dysfunction and Prevention of IDDM in NOD mice by Immunomodulators", Tonyobyo, vol. 29, No. 11, (1986), pp. 1055-1062 (English translation).
Chemical Abstracts vol. 106, #19, 1987, p. 531 154531-0 (Oya et al).
Sandberg et al, Diabetes, vol. 42, pp. 1845-1851, "Treatment with an Interleukin -1 Receptor . . . ", 1993.
Carr Deborah D.
Georgetown University Medical Center
LandOfFree
Treatment and/or prevention of type I diabetes mellitus with gam does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and/or prevention of type I diabetes mellitus with gam, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and/or prevention of type I diabetes mellitus with gam will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-705590